Evogene Ltd.
EVGN
$0.97
-$0.0255-2.56%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 427.00K | -5.42M | -6.60M | -3.98M | -3.98M |
| Total Depreciation and Amortization | 593.00K | 613.00K | 663.00K | 661.00K | 661.00K |
| Total Amortization of Deferred Charges | 334.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.00M | 154.00K | -577.00K | 530.00K | 530.00K |
| Change in Net Operating Assets | -562.00K | -803.00K | 590.00K | -1.52M | -1.52M |
| Cash from Operations | -5.21M | -5.46M | -5.93M | -4.32M | -4.32M |
| Capital Expenditure | -322.00K | -31.00K | -86.00K | -216.00K | -216.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 0.00 | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 9.08M | 3.24M | -500.00K | 3.86M | 3.86M |
| Cash from Investing | 8.76M | 3.21M | -586.00K | 3.64M | 3.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -206.00K | -231.00K | -212.00K | -211.00K | -211.00K |
| Issuance of Common Stock | 646.00K | 83.00K | 45.00K | 8.07M | 8.07M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -3.00K | 20.00K | -58.00K | -58.00K |
| Cash from Financing | 440.00K | -151.00K | -147.00K | 7.80M | 7.80M |
| Foreign Exchange rate Adjustments | -7.00K | -35.00K | 99.00K | -28.00K | -28.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.98M | -2.43M | -6.56M | 7.10M | 7.10M |